Teachers Retirement System of The State of Kentucky Invests $1.08 Million in Mirum Pharmaceuticals, Inc. $MIRM

Teachers Retirement System of The State of Kentucky acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,724 shares of the company’s stock, valued at approximately $1,079,000.

Other institutional investors also recently bought and sold shares of the company. MCF Advisors LLC boosted its holdings in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at approximately $33,000. Comerica Bank lifted its holdings in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the last quarter. CWM LLC lifted its holdings in Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after acquiring an additional 161 shares during the last quarter. Finally, Osaic Holdings Inc. grew its position in Mirum Pharmaceuticals by 46.5% in the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after acquiring an additional 351 shares during the period.

Insider Activity

In related news, insider Joanne Quan sold 6,911 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $90.27, for a total transaction of $623,855.97. Following the completion of the transaction, the insider directly owned 11,305 shares in the company, valued at $1,020,502.35. This trade represents a 37.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Patrick J. Heron bought 131,425 shares of the company’s stock in a transaction on Friday, January 23rd. The stock was purchased at an average cost of $68.48 per share, with a total value of $8,999,984.00. Following the completion of the transaction, the director owned 459,010 shares in the company, valued at $31,433,004.80. This represents a 40.12% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have sold 45,136 shares of company stock worth $4,352,029 in the last quarter. Insiders own 14.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Raymond James Financial restated a “strong-buy” rating and issued a $110.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Wall Street Zen cut Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 28th. Morgan Stanley raised their price objective on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Finally, Royal Bank Of Canada decreased their target price on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $117.00.

Mirum Pharmaceuticals Stock Down 1.8%

Shares of NASDAQ MIRM opened at $86.30 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98. The business’s 50 day moving average is $94.25 and its two-hundred day moving average is $79.89. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $109.28. The firm has a market cap of $5.21 billion, a price-to-earnings ratio of -179.79 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The firm had revenue of $148.93 million for the quarter, compared to analysts’ expectations of $141.78 million. During the same quarter in the prior year, the business earned $1.00 earnings per share. The company’s quarterly revenue was up 49.8% on a year-over-year basis. Research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.